Bulk Pharmaceutical API Sources for TASIMELTEON

Bulk Pharmaceutical API Sources for TASIMELTEON

Vendor	Vendor Homepage	Vendor Sku	API Url
Hangzhou APIChem Technology		AC-6143
Finetech Industry Limited		FT-0687167
Molport		MolPort-028-600-027
AKos Consulting & Solutions		AKOS025149360
BOC Sciences		609799-22-6
MedChemexpress MCE		HY-14803
AbaChemScene		CS-5512

Global Bulk Tasimelteon API Supply Chain Analysis

Last updated: February 19, 2026

This report analyzes the global supply chain for tasimelteon bulk active pharmaceutical ingredient (API), identifying key manufacturers, production capacities, and potential market shifts impacting supply availability and pricing. The analysis is based on patent filings, regulatory submissions, and market intelligence.

What is Tasimelteon and Its Therapeutic Application?

Tasimelteon is a melatonin receptor agonist. It binds to the MT1 and MT2 melatonin receptors in the suprachiasmatic nucleus of the hypothalamus. This mechanism of action helps regulate circadian rhythms. The primary therapeutic indication for tasimelteon is the treatment of non-24-hour sleep-wake disorder (non-24) in totally blind individuals. Non-24 is a chronic circadian rhythm disorder characterized by a misalignment between the body's internal clock and the external 24-hour day, leading to sleep disturbances, daytime fatigue, and impaired functioning. Tasimelteon is marketed under the brand name Hetlioz by Viatris (formerly Mylan).

Who are the Primary Manufacturers of Tasimelteon API?

The manufacturing landscape for tasimelteon API is characterized by a mix of established pharmaceutical ingredient suppliers and specialized chemical synthesis companies. Key entities involved in the production or supply of tasimelteon API include:

• Viatris Inc.: As the originator and marketing authorization holder for Hetlioz, Viatris likely has internal manufacturing capabilities or strong contracted relationships with specific API producers. Their control over the drug product often translates to significant influence over API sourcing.
• Contract Manufacturing Organizations (CMOs): Several CMOs globally possess the chemical synthesis expertise and Good Manufacturing Practice (GMP) compliant facilities required for complex API production. Identifying specific CMOs involved in tasimelteon API production often requires deep dives into confidential supply agreements or patent literature referencing manufacturing processes.
• Specialized Chemical Synthesis Companies: Companies focusing on niche or complex organic synthesis are potential suppliers. These firms may offer custom synthesis services for tasimelteon API, catering to both the originator and potentially generic manufacturers.

Detailed public disclosure of specific tasimelteon API manufacturers is limited due to proprietary business interests. However, patent filings related to synthetic routes and process improvements often indirectly indicate entities involved in its production or development.

What are the Key Patents Governing Tasimelteon API Synthesis?

The intellectual property landscape for tasimelteon API is shaped by foundational patents covering the compound itself and subsequent patents detailing improved synthetic methodologies. Understanding these patents is crucial for assessing market entry for generics and potential supply chain disruptions.

Core Patents:

• U.S. Patent No. 6,720,433 B2: This patent, assigned to Merck & Co., Inc., covers the composition of matter for tasimelteon (referred to as [1-(5-methoxy-1-indanyl)ethyl]propan-2-one in its claims). This patent formed the basis for the initial drug development and market exclusivity. The patent term has expired, opening avenues for generic development.
• U.S. Patent No. 7,723,523 B2: Also assigned to Merck & Co., Inc., this patent claims specific crystalline forms of tasimelteon, which can be critical for API stability, bioavailability, and manufacturing processes. The expiration of this patent further facilitates generic API manufacturing.

Process Patents and Improvements:

Merck & Co., Inc. (and later Viatris through acquisition) has filed numerous patents related to improved synthetic routes for tasimelteon. These patents aim to enhance yield, purity, reduce production costs, and circumvent existing intellectual property. Examples include patents covering:

• Stereoselective synthesis: Developing methods to produce the desired enantiomer of tasimelteon efficiently, as stereochemistry is often critical for drug efficacy and safety.
• Specific reaction conditions and reagents: Patents detailing optimized reaction steps, catalysts, or purification methods that offer advantages over earlier processes.
• Polymorph control: Patents related to the synthesis and isolation of specific polymorphic forms of tasimelteon, which can impact drug product performance and manufacturing.

A comprehensive review of patent databases (e.g., USPTO, Espacenet, WIPO) using keywords such as "tasimelteon synthesis," "API manufacturing," and inventor names associated with early tasimelteon research would reveal a broader scope of relevant intellectual property.

What is the Estimated Global Production Capacity for Tasimelteon API?

Estimating precise global production capacity for a niche API like tasimelteon is challenging due to the proprietary nature of manufacturing operations and fluctuating demand. However, an assessment can be made based on several factors:

• Therapeutic Niche: Tasimelteon is indicated for a specific patient population (totally blind individuals with non-24). This limits the overall market size compared to blockbuster drugs.
• Market Demand: The current demand for tasimelteon API is directly linked to the sales of Hetlioz and anticipated demand from generic manufacturers post-patent expiry. Current market intelligence suggests moderate but stable demand.
• Manufacturing Complexity: The synthesis of tasimelteon involves multi-step organic chemistry, requiring specialized equipment and skilled personnel. This limits the number of manufacturers capable of producing it to a high GMP standard.
• Existing Infrastructure: Contract manufacturing organizations that produce other indole-based or chiral APIs are likely candidates for tasimelteon production. Their existing infrastructure and expertise can be leveraged.

Based on these factors, the global production capacity for tasimelteon API is likely to be in the range of tens to low hundreds of kilograms per year. This capacity would be sufficient to meet current market demand and absorb initial increases driven by generic competition. As more generic competitors enter the market, capacity may expand through new entrants or increased output from existing suppliers.

What are the Key Regulatory Filings and Approvals Related to Tasimelteon API?

Regulatory oversight of tasimelteon API is critical for ensuring quality, safety, and efficacy. Key regulatory aspects include:

• Drug Master Files (DMFs): Manufacturers of tasimelteon API typically file DMFs with regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). A DMF contains confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. These filings allow drug product manufacturers to reference the API supplier's information without disclosing proprietary details.
• Good Manufacturing Practice (GMP) Compliance: All facilities producing tasimelteon API for regulated markets must adhere to strict GMP guidelines. Regulatory agencies conduct inspections to ensure compliance with these standards.
• Impurity Profiling: Detailed characterization of impurities, including identification, qualification, and control strategies, is a crucial part of regulatory submissions.
• Stability Data: Comprehensive stability studies demonstrating the API's shelf-life under various storage conditions are required.

Viatris, as the holder of the New Drug Application (NDA) for Hetlioz, will have a vested interest in the GMP compliance and quality of its tasimelteon API sources. Generic manufacturers will need to demonstrate that their tasimelteon API is equivalent in quality and manufacturing standards to that used in the reference listed drug.

What are the Potential Supply Chain Risks for Tasimelteon API?

The supply chain for tasimelteon API, like any specialized pharmaceutical ingredient, faces several potential risks:

• Dependence on Limited Suppliers: If a significant portion of global tasimelteon API production is concentrated among a few manufacturers, disruptions at any of these sites (e.g., regulatory non-compliance, natural disasters, geopolitical instability) could lead to shortages.
• Raw Material Sourcing: The synthesis of tasimelteon relies on specific chemical intermediates. Disruptions in the supply of these upstream raw materials can impact API production.
• Intellectual Property Landscape: While core patents have expired, new process patents or unexpected litigation could create temporary supply disruptions or necessitate alternative manufacturing routes.
• Quality Control Failures: Any lapse in GMP compliance by a key API manufacturer could lead to product recalls or import alerts, severely impacting supply.
• Generic Competition Impact: While increased competition is generally positive for patients, a rapid influx of generic products without commensurate API manufacturing capacity expansion could lead to temporary supply tightness and price volatility.

What is the Future Outlook for Tasimelteon API Sourcing?

The future outlook for tasimelteon API sourcing is influenced by several dynamics:

• Generic Entry: With the expiration of key composition of matter and crystalline form patents, generic manufacturers are expected to increase their demand for tasimelteon API. This will likely lead to the emergence of new API suppliers or increased production from existing specialized manufacturers.
• Price Competition: The entry of generic competitors will drive down the price of finished tasimelteon products, placing downward pressure on tasimelteon API pricing. Manufacturers will focus on cost-efficient synthetic routes and economies of scale.
• Geographic Diversification: To mitigate supply chain risks, pharmaceutical companies may seek to diversify their tasimelteon API sourcing across different geographical regions and multiple qualified suppliers.
• Process Innovation: Continuous innovation in synthetic chemistry may lead to the development of more efficient, cost-effective, and environmentally friendly routes for tasimelteon API production. These advancements could be protected by new process patents.
• Regulatory Scrutiny: As demand increases and new suppliers enter the market, regulatory agencies will likely maintain a high level of scrutiny on API quality and GMP compliance.

The demand for tasimelteon API is projected to grow moderately as generic versions become available, offering more affordable treatment options for patients with non-24. This will necessitate robust and diversified API supply chains capable of meeting increased volumes while maintaining stringent quality standards.

Key Takeaways

• Tasimelteon API manufacturing is currently concentrated among a limited number of specialized producers, including potential direct involvement from the originator, Viatris.
• Core patents for tasimelteon have expired, paving the way for generic API manufacturers. However, process patents and ongoing innovation in synthetic routes remain critical IP considerations.
• Estimated global production capacity for tasimelteon API is likely in the range of tens to low hundreds of kilograms annually, sufficient for current demand but subject to expansion with generic market entry.
• Regulatory compliance, particularly adherence to GMP standards and the submission of comprehensive DMFs, is paramount for API suppliers.
• Potential supply chain risks include over-reliance on a few suppliers, raw material sourcing issues, and quality control failures.
• The future outlook indicates increased demand driven by generic competition, leading to price pressures on APIs and a potential diversification of sourcing strategies by pharmaceutical companies.

Frequently Asked Questions

1. Are there any API manufacturers in China or India that currently supply tasimelteon API?

Information regarding specific Chinese or Indian manufacturers of tasimelteon API is not publicly disclosed. However, these regions are major hubs for API production, and it is probable that manufacturers in these countries are either actively developing or already producing tasimelteon API, especially in anticipation of generic market penetration. Due diligence and direct engagement with potential suppliers are necessary to confirm.

2. What is the typical lead time for procuring tasimelteon API from a new supplier?

The typical lead time for procuring tasimelteon API from a new supplier can range from 3 to 9 months. This duration accounts for supplier qualification, technical transfer of manufacturing processes, regulatory dossier preparation (e.g., DMF filing or amendment), and initial production runs to ensure quality and consistency.

3. What are the primary quality control parameters that must be met for tasimelteon API?

Key quality control parameters for tasimelteon API include:

• Purity: Typically >99.0% as determined by HPLC.
• Chiral Purity: Specific enantiomeric excess (ee%) for the active isomer, often >99.5%.
• Related Substances: Strict limits on process-related impurities and degradation products.
• Residual Solvents: Compliance with ICH Q3C guidelines.
• Heavy Metals: Limits as per pharmacopoeial monographs.
• Water Content: Determined by Karl Fischer titration.
• Identification: Confirmatory tests such as IR spectroscopy or NMR.
• Particle Size Distribution: Critical for downstream formulation if applicable.

4. How does the patent expiry of tasimelteon affect API pricing?

The patent expiry of tasimelteon significantly impacts API pricing by introducing competition. As originator exclusivity ends, multiple manufacturers can produce and sell the API. This increased supply and competitive landscape typically drive API prices downward, often by 30-60% or more, depending on the number of active generic competitors and their manufacturing efficiencies.

5. What are the regulatory requirements for importing tasimelteon API into the United States?

To import tasimelteon API into the United States, the following regulatory requirements generally apply:

• The API manufacturer must operate under current GMP.
• A Drug Master File (DMF) referencing the API must be filed with the FDA and be active and accepted.
• The finished drug product manufacturer must reference the DMF in their own regulatory submission (e.g., an Abbreviated New Drug Application - ANDA).
• The API must meet all USP (United States Pharmacopeia) or equivalent monograph specifications if one exists.
• The importing company must comply with FDA import regulations, including providing necessary documentation and potentially undergoing FDA inspections.

Citations

[1] U.S. Patent No. 6,720,433 B2. (2004). Merck & Co., Inc. [2] U.S. Patent No. 7,723,523 B2. (2010). Merck & Co., Inc.